Cite
Serum WFA+-M2 BP is a non-invasive liver fibrosis marker that can predict the efficacy of direct-acting anti-viral-based triple therapy for chronic hepatitis C.
MLA
Ura, K., et al. “Serum WFA+-M2 BP Is a Non-Invasive Liver Fibrosis Marker That Can Predict the Efficacy of Direct-Acting Anti-Viral-Based Triple Therapy for Chronic Hepatitis C.” Alimentary Pharmacology & Therapeutics, vol. 43, no. 1, Jan. 2016, pp. 114–24. EBSCOhost, https://doi.org/10.1111/apt.13431.
APA
Ura, K., Furusyo, N., Ogawa, E., Hayashi, T., Mukae, H., Shimizu, M., Toyoda, K., Murata, M., & Hayashi, J. (2016). Serum WFA+-M2 BP is a non-invasive liver fibrosis marker that can predict the efficacy of direct-acting anti-viral-based triple therapy for chronic hepatitis C. Alimentary Pharmacology & Therapeutics, 43(1), 114–124. https://doi.org/10.1111/apt.13431
Chicago
Ura, K., N. Furusyo, E. Ogawa, T. Hayashi, H. Mukae, M. Shimizu, K. Toyoda, M. Murata, and J. Hayashi. 2016. “Serum WFA+-M2 BP Is a Non-Invasive Liver Fibrosis Marker That Can Predict the Efficacy of Direct-Acting Anti-Viral-Based Triple Therapy for Chronic Hepatitis C.” Alimentary Pharmacology & Therapeutics 43 (1): 114–24. doi:10.1111/apt.13431.